About Travere Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://travere.com/
Frequently Asked Questions
What is the 52-week range for TVTX?
The 52-week high is $68.73 and the 52-week low is $22.59.
What is the P/E ratio for TVTX?
The P/E ratio data is currently unavailable.
What is the dividend yield for TVTX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -55.79%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -7.35%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 29.77.
Analyst Recommendation Trends
Wall Street analyst consensus for TVTX over the last few months:
Latest TVTX News
Travere to Present New Data Supporting FILSPARI® (sparsentan) as Foundational Treatment in IgA Nephropathy and FSGS at ASN Kidney Week 2026
SAN DIEGO, October 02, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, CO, October 21-25. The presentations highlight compelling new data on FILSPARI® (sparsentan) in patients with IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS).
Guggenheim Maintains Buy on Travere Therapeutics, Raises Price Target to $89
Guggenheim analyst Vamil Divan maintains Travere Therapeutics (NASDAQ:TVTX) with a Buy and raises the price target from $75 to $89.
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis
SAN DIEGO, September 23, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Patent Application No. 19/253,120, titled "Biphenyl Sulfonamide Compounds for the Treatment of Kidney Diseases or Disorders," directed to certain methods of using FILSPARI® (sparsentan) in focal segmental glomerulosclerosis (FSGS). Upon issuance, the patent is expected to provide U.S. patent coverage for certain
Travere Therapeutics (TVTX) Sets CEO Handover For December 2026
Travere Therapeutics (NasdaqGM:TVTX) announced a planned CEO and President transition effective December 1, 2026. Dr. Eric Dube will step down from his roles as CEO and President as part of the scheduled leadership change. Bradley L. Campbell has been appointed to succeed Dr. Dube, bringing experience from the rare disease biopharmaceutical sector. This CEO and President transition at Travere Therapeutics is an important development to set alongside the rest of the analysis. We have also...
SBIO: Big Pharma Needs What This Fund Owns
The ALPS Medical Breakthroughs ETF is a Buy, as its pullback offers a better entry into late-stage biotech. Click for more on the SBIO ETF.
Travere Therapeutics (TVTX) Stock May Trade Above Fair Value Today
Travere Therapeutics has delivered a very large share price gain over the past few years, which naturally puts the focus on what investors are paying for its sales today. With the stock now reflecting years of optimism, the immediate question is how well the current valuation lines up with the revenue the business is actually generating. Over the last 3 years the share price has risen by roughly 7x, so anyone looking at Travere Therapeutics now is effectively asking how much of that move is...
Wedbush Reiterates Outperform on Travere Therapeutics, Maintains $76 Price Target
Wedbush analyst Laura Chico reiterates Travere Therapeutics (NASDAQ:TVTX) with a Outperform and maintains $76 price target.
HC Wainwright & Co. Reiterates Buy on Travere Therapeutics, Maintains $67 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Travere Therapeutics (NASDAQ:TVTX) with a Buy and maintains $67 price target.
Travere Therapeutics Announces Planned Chief Executive Officer Transition
SAN DIEGO, September 21, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The Company’s Board of Directors has unanimously appointed Bradley L. Campbell, former president and CEO of Amicus Therapeutics, now a wholly owned subsidiary of BioMarin Pharmaceutical Inc., to succeed Dr. Dube as president and chief executive officer a
Travere Therapeutics Appoints Bradley L. Campbell President, CEO, Effective Dec. 1, Succeeding Eric Dube
Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced that Eric Dube, Ph.D., has made the difficult and personal decision to step down as president and chief executive officer to focus on his health and family. The
Travere Therapeutics (NASDAQ:TVTX) Passes Minervini Trend Template With High-Growth Momentum
TVTX passes the Minervini Trend Template and high-growth momentum screen, showing a strong Stage 2 uptrend with accelerating sales and EPS.
Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
SAN DIEGO, September 17, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on Thursday, September 24, 2026, at 10:30 a.m. ET.
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, September 11, 2026--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, consisting of inducement restricted stock units, or RSUs, covering an aggregate of 56,220 shares of its common stock. These inducement RSUs are subject to the terms of Travere’s 2018 Equity Incentive Plan ("2018 Plan") but were granted outside of the 2018 Plan and were grante
Travere Therapeutics' Outlook Brightens As Turnaround Looms
Biotech name Travere Therapeutics is not profitable yet but a turnaround may be around the corner as the stock hovers near a buy zone.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-17 | Heerma Peter | -8,282 | - | - |
| 2026-09-17 | Heerma Peter | -8,282 | $65.0709 | $538,917 |
| 2026-09-17 | Heerma Peter | +8,282 | $22.4 | $185,517 |
| 2026-09-17 | Dube Eric M | -108,493 | - | - |
| 2026-09-17 | Dube Eric M | -6,802 | $64.9508 | $441,795 |
| 2026-09-17 | Dube Eric M | -101,691 | $64.5866 | $6,567,876 |
| 2026-09-17 | Dube Eric M | +108,493 | $23.34 | $2,532,227 |
| 2026-09-16 | Heerma Peter | -17,717 | - | - |
| 2026-09-16 | Heerma Peter | -55,000 | - | - |
| 2026-09-16 | Heerma Peter | -100,000 | - | - |
| 2026-09-16 | Heerma Peter | -79,113 | $63.6546 | $5,035,906 |
| 2026-09-16 | Heerma Peter | -93,604 | $63.2471 | $5,920,182 |
| 2026-09-16 | Heerma Peter | +17,717 | $26.88 | $476,233 |
| 2026-09-16 | Heerma Peter | +55,000 | $15.46 | $850,300 |
| 2026-09-16 | Heerma Peter | +100,000 | $11.25 | $1,125,000 |
| 2026-09-16 | Dube Eric M | -195,841 | - | - |
| 2026-09-16 | Dube Eric M | -96,125 | $63.6389 | $6,117,289 |
| 2026-09-16 | Dube Eric M | -99,716 | $63.2593 | $6,307,964 |
| 2026-09-16 | Dube Eric M | +195,841 | $23.34 | $4,570,929 |
| 2026-09-16 | ROTE WILLIAM E. | -57,500 | - | - |
| 2026-09-16 | ROTE WILLIAM E. | -55,000 | - | - |
| 2026-09-16 | ROTE WILLIAM E. | -350 | - | - |
| 2026-09-16 | ROTE WILLIAM E. | -47,746 | $63.6126 | $3,037,247 |
| 2026-09-16 | ROTE WILLIAM E. | -65,104 | $63.1205 | $4,109,397 |
| 2026-09-16 | ROTE WILLIAM E. | +57,500 | $26.88 | $1,545,600 |
| 2026-09-16 | ROTE WILLIAM E. | +55,000 | $15.46 | $850,300 |
| 2026-09-16 | ROTE WILLIAM E. | +350 | $17.96 | $6,286 |
| 2026-09-15 | Cline Christopher R. | -20,000 | - | - |
| 2026-09-15 | Cline Christopher R. | -400 | $65.31 | $26,124 |
| 2026-09-15 | Cline Christopher R. | -1,900 | $63.6865 | $121,004 |
| 2026-09-15 | Cline Christopher R. | -20,735 | $62.6079 | $1,298,175 |
| 2026-09-15 | Cline Christopher R. | -27,473 | $61.9969 | $1,703,241 |
| 2026-09-15 | Cline Christopher R. | +20,000 | $17.44 | $348,800 |
| 2026-09-15 | Inrig Jula | -32,395 | - | - |
| 2026-09-15 | Inrig Jula | -400 | $65.31 | $26,124 |
| 2026-09-15 | Inrig Jula | -1,600 | $63.685 | $101,896 |
| 2026-09-15 | Inrig Jula | -17,284 | $62.6242 | $1,082,397 |
| 2026-09-15 | Inrig Jula | -25,390 | $62.0167 | $1,574,604 |
| 2026-09-15 | Inrig Jula | +32,395 | $8.93 | $289,287 |
| 2026-09-15 | Calvin Sandra | -1,625 | - | - |
| 2026-09-15 | Calvin Sandra | -1,250 | - | - |
| 2026-09-15 | Calvin Sandra | -2,500 | - | - |
| 2026-09-15 | Calvin Sandra | -300 | $63.6633 | $19,099 |
| 2026-09-15 | Calvin Sandra | -800 | $62.8481 | $50,278 |
| 2026-09-15 | Calvin Sandra | -4,275 | $62.135 | $265,627 |
| 2026-09-15 | Calvin Sandra | +1,625 | $20.46 | $33,248 |
| 2026-09-15 | Calvin Sandra | +1,250 | $22.4 | $28,000 |
| 2026-09-15 | Calvin Sandra | +2,500 | $27.5 | $68,750 |
| 2026-09-15 | Heerma Peter | -36,526 | - | - |
| 2026-09-15 | Heerma Peter | -1,381 | - | - |
| 2026-09-15 | Heerma Peter | -39,283 | - | - |
| 2026-09-15 | Heerma Peter | -1,431 | $65.3093 | $93,458 |
| 2026-09-15 | Heerma Peter | -1,400 | $63.6521 | $89,113 |
| 2026-09-15 | Heerma Peter | -27,421 | $62.5936 | $1,716,379 |
| 2026-09-15 | Heerma Peter | -71,938 | $62.0517 | $4,463,875 |
| 2026-09-15 | Heerma Peter | +36,526 | $8.93 | $326,177 |
| 2026-09-15 | Heerma Peter | +1,381 | $22.4 | $30,934 |
| 2026-09-15 | Heerma Peter | +39,283 | $26.88 | $1,055,927 |
| 2026-09-15 | Dube Eric M | -95,666 | - | - |
| 2026-09-15 | Dube Eric M | -270 | $65.31 | $17,634 |
| 2026-09-15 | Dube Eric M | -3,102 | $63.6434 | $197,422 |
| 2026-09-15 | Dube Eric M | -28,796 | $62.6553 | $1,804,222 |
| 2026-09-15 | Dube Eric M | -63,498 | $61.9945 | $3,936,527 |
| 2026-09-15 | Dube Eric M | +95,666 | $23.34 | $2,232,844 |
| 2026-09-15 | ROTE WILLIAM E. | -39,650 | - | - |
| 2026-09-15 | ROTE WILLIAM E. | -39,000 | - | - |
| 2026-09-15 | ROTE WILLIAM E. | -270 | $65.31 | $17,634 |
| 2026-09-15 | ROTE WILLIAM E. | -3,000 | $63.6508 | $190,952 |
| 2026-09-15 | ROTE WILLIAM E. | -29,021 | $62.6552 | $1,818,317 |
| 2026-09-15 | ROTE WILLIAM E. | -63,907 | $61.994 | $3,961,851 |
| 2026-09-15 | ROTE WILLIAM E. | +39,650 | $17.96 | $712,114 |
| 2026-09-15 | ROTE WILLIAM E. | +39,000 | $25.25 | $984,750 |
| 2026-09-15 | REED ELIZABETH E | -37,500 | - | - |
| 2026-09-15 | REED ELIZABETH E | -300 | $65.31 | $19,593 |
| 2026-09-15 | REED ELIZABETH E | -1,400 | $63.6902 | $89,166 |
| 2026-09-15 | REED ELIZABETH E | -13,874 | $62.6326 | $868,965 |
| 2026-09-15 | REED ELIZABETH E | -21,926 | $62.0255 | $1,359,971 |
| 2026-09-15 | REED ELIZABETH E | +37,500 | $15.46 | $579,750 |
| 2026-09-10 | Meckler Jeffrey A | -10,000 | - | - |
| 2026-09-10 | Meckler Jeffrey A | -10,000 | - | - |
| 2026-09-10 | Meckler Jeffrey A | -3,100 | $68.088 | $211,073 |
| 2026-09-10 | Meckler Jeffrey A | -14,000 | $67.4634 | $944,488 |
| 2026-09-10 | Meckler Jeffrey A | -1,200 | $66.15 | $79,380 |
| 2026-09-10 | Meckler Jeffrey A | -1,700 | $65.3917 | $111,166 |
| 2026-09-10 | Meckler Jeffrey A | +10,000 | $26.52 | $265,200 |
| 2026-09-10 | Meckler Jeffrey A | +10,000 | $17.44 | $174,400 |
| 2026-09-02 | Cline Christopher R. | -642 | $66.37 | $42,610 |
| 2026-08-18 | LYONS GARY A | -5,000 | - | - |
| 2026-08-18 | LYONS GARY A | -900 | $63.8557 | $57,470 |
| 2026-08-18 | LYONS GARY A | -4,100 | $63.2659 | $259,390 |
| 2026-08-18 | LYONS GARY A | +5,000 | $17.44 | $87,200 |
| 2026-08-17 | LYONS GARY A | -5,000 | - | - |
| 2026-08-17 | LYONS GARY A | -500 | $64.162 | $32,081 |
| 2026-08-17 | LYONS GARY A | -2,600 | $63.4999 | $165,100 |
| 2026-08-17 | LYONS GARY A | -1,900 | $62.5289 | $118,805 |
| 2026-08-17 | LYONS GARY A | +5,000 | $17.44 | $87,200 |
| 2026-06-22 | Inrig Jula | -468 | - | - |
| 2026-06-12 | Baynes Roy D. | -4,500 | - | - |
| 2026-06-12 | Baynes Roy D. | -4,500 | $50 | $225,000 |
| 2026-06-12 | Baynes Roy D. | +4,500 | $21.38 | $96,210 |
| 2026-06-12 | Coughlin Timothy | -10,000 | - | - |
| 2026-06-12 | Coughlin Timothy | -10,000 | $50.0747 | $500,747 |
| 2026-06-12 | Coughlin Timothy | +10,000 | $26.52 | $265,200 |
| 2026-05-19 | Baynes Roy D. | +12,000 | - | - |
| 2026-05-19 | Baynes Roy D. | +4,000 | - | - |
| 2026-05-19 | Poole Sandra | +12,000 | - | - |
| 2026-05-19 | Poole Sandra | +4,000 | - | - |
| 2026-05-19 | Bruhn Suzanne Louise | +12,000 | - | - |
| 2026-05-19 | Bruhn Suzanne Louise | +4,000 | - | - |
| 2026-05-19 | Meckler Jeffrey A | +12,000 | - | - |
| 2026-05-19 | Meckler Jeffrey A | +4,000 | - | - |
| 2026-05-19 | Orwin John A | +12,000 | - | - |
| 2026-05-19 | Orwin John A | +4,000 | - | - |
| 2026-05-19 | Squarer Ron | +12,000 | - | - |
| 2026-05-19 | Squarer Ron | +4,000 | - | - |
| 2026-05-19 | Coughlin Timothy | +12,000 | - | - |
| 2026-05-19 | Coughlin Timothy | +4,000 | - | - |
| 2026-05-19 | Williams Brinkley Ruth | +12,000 | - | - |
| 2026-05-19 | Williams Brinkley Ruth | +4,000 | - | - |
| 2026-05-19 | LYONS GARY A | +12,000 | - | - |
| 2026-05-19 | LYONS GARY A | +4,000 | - | - |
| 2026-05-15 | Coughlin Timothy | -3,250 | $43.49 | $141,343 |
| 2026-05-06 | Cline Christopher R. | -310 | $43.95 | $13,625 |
| 2026-05-06 | Inrig Jula | -311 | $43.95 | $13,668 |
| 2026-05-06 | Dube Eric M | -22,500 | $43.95 | $988,875 |
| 2026-05-06 | ROTE WILLIAM E. | -2,763 | $43.95 | $121,434 |
| 2026-05-06 | REED ELIZABETH E | -2,076 | $43.95 | $91,240 |
| 2026-05-05 | Cline Christopher R. | -2,181 | $46.65 | $101,744 |
| 2026-05-05 | Inrig Jula | -2,174 | $46.65 | $101,417 |
| 2026-05-05 | Heerma Peter | -2,174 | $46.65 | $101,417 |
| 2026-05-05 | Baynes Roy D. | -4,500 | - | - |
| 2026-05-05 | Baynes Roy D. | -4,500 | $46.65 | $209,925 |
| 2026-05-05 | Baynes Roy D. | +4,500 | $18.27 | $82,215 |
| 2026-05-05 | REED ELIZABETH E | -2,174 | $46.65 | $101,417 |
| 2026-05-04 | Cline Christopher R. | -4,250 | - | - |
| 2026-05-04 | Cline Christopher R. | +8,500 | - | - |
| 2026-05-04 | Cline Christopher R. | +4,250 | - | - |
| 2026-05-04 | Inrig Jula | -4,250 | - | - |
| 2026-05-04 | Inrig Jula | +8,500 | - | - |
| 2026-05-04 | Inrig Jula | -20,000 | - | - |
| 2026-05-04 | Inrig Jula | +4,250 | - | - |
| 2026-05-04 | Inrig Jula | -20,000 | $45 | $900,000 |
| 2026-05-04 | Inrig Jula | +20,000 | $22.4 | $448,000 |
| 2026-05-04 | Heerma Peter | -4,250 | - | - |
| 2026-05-04 | Heerma Peter | +8,500 | - | - |
| 2026-05-04 | Heerma Peter | +4,250 | - | - |
| 2026-05-04 | Dube Eric M | -22,500 | - | - |
| 2026-05-04 | Dube Eric M | +45,000 | - | - |
| 2026-05-04 | Dube Eric M | +22,500 | - | - |
| 2026-05-04 | ROTE WILLIAM E. | -4,250 | - | - |
| 2026-05-04 | ROTE WILLIAM E. | +8,500 | - | - |
| 2026-05-04 | ROTE WILLIAM E. | +4,250 | - | - |
| 2026-05-04 | Meckler Jeffrey A | -8,000 | - | - |
| 2026-05-04 | Meckler Jeffrey A | -8,000 | $45 | $360,000 |
| 2026-05-04 | Meckler Jeffrey A | +8,000 | $16.33 | $130,640 |
| 2026-05-04 | REED ELIZABETH E | -4,250 | - | - |
| 2026-05-04 | REED ELIZABETH E | +8,500 | - | - |
| 2026-05-04 | REED ELIZABETH E | -20,000 | - | - |
| 2026-05-04 | REED ELIZABETH E | +4,250 | - | - |
| 2026-05-04 | REED ELIZABETH E | -20,000 | $45 | $900,000 |
| 2026-05-04 | REED ELIZABETH E | +20,000 | $17.96 | $359,200 |
| 2026-05-01 | Baynes Roy D. | -9,750 | - | - |
| 2026-05-01 | Baynes Roy D. | -9,750 | $44.22 | $431,145 |
| 2026-05-01 | Baynes Roy D. | +9,750 | $6.82 | $66,495 |
| 2026-04-22 | ROTE WILLIAM E. | -9,100 | $39.09 | $355,719 |
| 2026-04-15 | Cline Christopher R. | -1,014 | $42.61 | $43,207 |
| 2026-04-15 | Inrig Jula | -1,018 | $42.61 | $43,377 |
| 2026-04-15 | Dube Eric M | -20 | $42.66 | $853 |
| 2026-04-15 | Dube Eric M | -7,165 | $41.75 | $299,139 |
| 2026-04-15 | Dube Eric M | -56,815 | $41.01 | $2,329,983 |
| 2026-04-15 | REED ELIZABETH E | -1,559 | $42.53 | $66,304 |
| 2026-04-15 | REED ELIZABETH E | -5,226 | $41.62 | $217,506 |
| 2026-04-14 | Calvin Sandra | -6,500 | - | - |
| 2026-04-14 | Calvin Sandra | -6,250 | - | - |
| 2026-04-14 | Calvin Sandra | -2,500 | - | - |
| 2026-04-14 | Calvin Sandra | -21,977 | $41.07 | $902,595 |
| 2026-04-14 | Calvin Sandra | +6,500 | $20.46 | $132,990 |
| 2026-04-14 | Calvin Sandra | +6,250 | $8.93 | $55,813 |
| 2026-04-14 | Calvin Sandra | +2,500 | $22.4 | $56,000 |
| 2026-04-14 | Baynes Roy D. | -6,750 | - | - |
| 2026-04-14 | Baynes Roy D. | -4,500 | - | - |
| 2026-04-14 | Baynes Roy D. | -4,500 | - | - |
| 2026-04-14 | Baynes Roy D. | -9,000 | - | - |
| 2026-04-14 | Baynes Roy D. | -8,000 | - | - |
| 2026-04-14 | Baynes Roy D. | -6,750 | $42.12 | $284,310 |
| 2026-04-14 | Baynes Roy D. | -26,000 | $41.07 | $1,067,820 |
| 2026-04-14 | Baynes Roy D. | +6,750 | $17.11 | $115,493 |
| 2026-04-14 | Baynes Roy D. | +4,500 | $21.38 | $96,210 |
| 2026-04-14 | Baynes Roy D. | +4,500 | $18.27 | $82,215 |
| 2026-04-14 | Baynes Roy D. | +9,000 | $15.43 | $138,870 |
| 2026-04-14 | Baynes Roy D. | +8,000 | $17.94 | $143,520 |
| 2026-04-14 | LYONS GARY A | +8,000 | - | - |
| 2026-04-14 | LYONS GARY A | -8,000 | $41.07 | $328,560 |
| 2026-04-14 | LYONS GARY A | +8,000 | $16.33 | $130,640 |
| 2026-04-14 | Cline Christopher R. | -7,239 | $41.9288 | $303,523 |
| 2026-04-14 | Cline Christopher R. | -9 | $41.07 | $370 |
| 2026-04-14 | Inrig Jula | -7,215 | $41.9288 | $302,516 |
| 2026-04-14 | Heerma Peter | -7,215 | $41.9288 | $302,516 |
| 2026-04-14 | REED ELIZABETH E | -20,000 | - | - |
| 2026-04-14 | REED ELIZABETH E | -10,000 | - | - |
| 2026-04-14 | REED ELIZABETH E | -7,500 | - | - |
| 2026-04-14 | REED ELIZABETH E | -7,215 | $41.9288 | $302,516 |
| 2026-04-14 | REED ELIZABETH E | -37,500 | $41.07 | $1,540,125 |
| 2026-04-14 | REED ELIZABETH E | +7,500 | $15.46 | $115,950 |
| 2026-04-14 | REED ELIZABETH E | +20,000 | $17.96 | $359,200 |
| 2026-04-14 | REED ELIZABETH E | +10,000 | $19.08 | $190,800 |
| 2026-04-13 | Cline Christopher R. | -65 | $28.85 | $1,875 |
| 2026-04-13 | Cline Christopher R. | +14,000 | - | - |
| 2026-04-13 | Inrig Jula | +14,000 | - | - |
| 2026-04-13 | Heerma Peter | +14,000 | - | - |
| 2026-04-13 | Dube Eric M | +64,000 | - | - |
| 2026-04-13 | ROTE WILLIAM E. | +14,000 | - | - |
| 2026-04-13 | REED ELIZABETH E | +14,000 | - | - |
| 2026-04-06 | Baynes Roy D. | -10,000 | - | - |
| 2026-04-06 | Baynes Roy D. | -10,000 | $33 | $330,000 |
| 2026-04-06 | Baynes Roy D. | +10,000 | $26.52 | $265,200 |
| 2026-04-01 | Dube Eric M | -60,000 | - | - |
| 2026-04-01 | Dube Eric M | -25,098 | $31.46 | $789,583 |
| 2026-04-01 | Dube Eric M | -34,902 | $30.55 | $1,066,256 |
| 2026-04-01 | Dube Eric M | +60,000 | $15.46 | $927,600 |
| 2026-04-01 | REED ELIZABETH E | -10,000 | - | - |
| 2026-04-01 | REED ELIZABETH E | -10,000 | $30 | $300,000 |
| 2026-04-01 | REED ELIZABETH E | +10,000 | $15.46 | $154,600 |
| 2026-03-16 | REED ELIZABETH E | -10,000 | - | - |
| 2026-03-16 | REED ELIZABETH E | -10,000 | $28.0861 | $280,861 |
| 2026-03-16 | REED ELIZABETH E | +10,000 | $19.08 | $190,800 |
| 2026-02-20 | Dube Eric M | -60,000 | - | - |
| 2026-02-20 | Dube Eric M | -60,000 | $30.0961 | $1,805,766 |
| 2026-02-20 | Dube Eric M | +60,000 | $15.46 | $927,600 |
| 2026-02-17 | REED ELIZABETH E | -10,000 | - | - |
| 2026-02-17 | REED ELIZABETH E | -4,321 | $28.262 | $122,120 |
| 2026-02-17 | REED ELIZABETH E | -5,679 | $27.504 | $156,195 |
| 2026-02-17 | REED ELIZABETH E | +10,000 | $19.08 | $190,800 |
| 2026-02-04 | Cline Christopher R. | -110 | $32.9 | $3,619 |
| 2026-02-04 | Cline Christopher R. | -1,635 | $32.14 | $52,549 |
| 2026-02-04 | Inrig Jula | -232 | $32.85 | $7,621 |
| 2026-02-04 | Inrig Jula | -1,547 | $32.11 | $49,674 |
| 2026-02-04 | REED ELIZABETH E | -509 | $32.74 | $16,665 |
| 2026-02-04 | REED ELIZABETH E | -2,485 | $32.07 | $79,694 |
| 2026-02-03 | Cline Christopher R. | -7,242 | $32.12 | $232,613 |
| 2026-02-03 | Inrig Jula | -6,956 | $32.12 | $223,427 |
| 2026-02-03 | Calvin Sandra | -4,333 | $32.12 | $139,176 |
| 2026-02-03 | Heerma Peter | -7,310 | $32.12 | $234,797 |
| 2026-02-03 | Dube Eric M | -33,635 | $32.7 | $1,099,865 |
| 2026-02-03 | Dube Eric M | -66,452 | $32.06 | $2,130,451 |
| 2026-02-03 | ROTE WILLIAM E. | -12,446 | $32.87 | $409,100 |
| 2026-02-03 | REED ELIZABETH E | -7,175 | $32.12 | $230,461 |
| 2026-01-31 | Cline Christopher R. | +75,000 | - | - |
| 2026-01-31 | Cline Christopher R. | +28,130 | - | - |
| 2026-01-31 | Inrig Jula | +75,000 | - | - |
| 2026-01-31 | Inrig Jula | +28,130 | - | - |
| 2026-01-31 | Calvin Sandra | +20,160 | - | - |
| 2026-01-31 | Calvin Sandra | +15,180 | - | - |
| 2026-01-31 | Heerma Peter | +69,640 | - | - |
| 2026-01-31 | Heerma Peter | +26,120 | - | - |
| 2026-01-31 | Dube Eric M | +303,600 | - | - |
| 2026-01-31 | Dube Eric M | +113,800 | - | - |
| 2026-01-31 | ROTE WILLIAM E. | +53,570 | - | - |
| 2026-01-31 | ROTE WILLIAM E. | +20,090 | - | - |
| 2026-01-31 | REED ELIZABETH E | +66,960 | - | - |
| 2026-01-31 | REED ELIZABETH E | +25,110 | - | - |
| 2026-01-27 | Dube Eric M | -51,865 | - | - |
| 2026-01-27 | Dube Eric M | -51,865 | $30.097 | $1,560,981 |
| 2026-01-27 | Dube Eric M | +51,865 | $15.46 | $801,833 |
| 2026-01-23 | Dube Eric M | -8,135 | - | - |
| 2026-01-23 | Dube Eric M | -8,135 | $30.0127 | $244,153 |
| 2026-01-23 | Dube Eric M | +8,135 | $15.46 | $125,767 |
| 2026-01-20 | REED ELIZABETH E | -10,000 | - | - |
| 2026-01-20 | REED ELIZABETH E | -10,000 | $27.342 | $273,420 |
| 2026-01-20 | REED ELIZABETH E | +10,000 | $19.08 | $190,800 |
| 2026-01-06 | Inrig Jula | -445 | $37.75 | $16,799 |
| 2026-01-05 | Inrig Jula | -2,031 | $40.18 | $81,606 |
| 2025-12-24 | Inrig Jula | -15,000 | - | - |
| 2025-12-24 | Inrig Jula | -15,000 | $42.0003 | $630,005 |
| 2025-12-24 | Inrig Jula | +15,000 | $8.93 | $133,950 |
| 2025-12-24 | Calvin Sandra | -7,402 | $40 | $296,080 |
| 2025-12-24 | Heerma Peter | -4,980 | $40 | $199,200 |
| 2025-12-24 | ROTE WILLIAM E. | -60,000 | - | - |
| 2025-12-24 | ROTE WILLIAM E. | -60,000 | $40.103 | $2,406,180 |
| 2025-12-24 | ROTE WILLIAM E. | +60,000 | $20.61 | $1,236,600 |
| 2025-12-15 | Calvin Sandra | -2,910 | $36 | $104,760 |
| 2025-12-01 | Cline Christopher R. | -20,000 | - | - |
| 2025-12-01 | Cline Christopher R. | -20,000 | $35.0101 | $700,202 |
| 2025-12-01 | Cline Christopher R. | +20,000 | $16.23 | $324,600 |
| 2025-11-04 | Calvin Sandra | -6,250 | - | - |
| 2025-11-04 | Calvin Sandra | -12,500 | - | - |
| 2025-11-04 | Calvin Sandra | -15,000 | - | - |
| 2025-11-04 | Calvin Sandra | -17,500 | - | - |
| 2025-11-04 | Calvin Sandra | -10,000 | - | - |
| 2025-11-04 | Calvin Sandra | -67,115 | $36 | $2,416,140 |
| 2025-11-04 | Calvin Sandra | +6,250 | $8.93 | $55,813 |
| 2025-11-04 | Calvin Sandra | +12,500 | $22.4 | $280,000 |
| 2025-11-04 | Calvin Sandra | +15,000 | $27.5 | $412,500 |
| 2025-11-04 | Calvin Sandra | +17,500 | $26.88 | $470,400 |
| 2025-11-04 | Calvin Sandra | +10,000 | $25.25 | $252,500 |
| 2025-11-03 | Heerma Peter | -1,078 | - | - |
| 2025-10-31 | Heerma Peter | -5,591 | $35 | $195,685 |
| 2025-10-31 | Coughlin Timothy | -10,000 | - | - |
| 2025-10-31 | Coughlin Timothy | -8,000 | - | - |
| 2025-10-31 | Coughlin Timothy | -18,000 | $35.0334 | $630,601 |
| 2025-10-31 | Coughlin Timothy | +10,000 | $17.44 | $174,400 |
| 2025-10-31 | Coughlin Timothy | +8,000 | $16.33 | $130,640 |
| 2025-10-29 | Dube Eric M | -27,128 | - | - |
| 2025-10-29 | Dube Eric M | -27,128 | $30.1192 | $817,074 |
| 2025-10-29 | Dube Eric M | +27,128 | $15.46 | $419,399 |
| 2025-10-28 | Heerma Peter | -2,662 | $30 | $79,860 |
| 2025-10-28 | Dube Eric M | -92,872 | - | - |
| 2025-10-28 | Dube Eric M | -92,872 | $30.379 | $2,821,358 |
| 2025-10-28 | Dube Eric M | +92,872 | $15.46 | $1,435,801 |